R3 Vascular Reports the Initiation of Its First-In-Human Clinical Study
“Clinical development of our bioresorbable sirolimus-eluting scaffold for treating peripheral arterial disease (PAD) is proceeding ahead of schedule and achieving outstanding procedural results,” said Kamal Ramzipoor, CEO of R3 Vascular.
Excerpt from the Press Release:
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE® Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.
The R3 Vascular platform incorporates an innovative scaffold design and bioresorbable polymer technology resulting in biomechanical performance comparable to metallic stents. The MAGNITUDE BRS, specifically designed to balance mechanical strength and flexibility uses a novel bioresorbable polymer that provides the structural support needed in this complex vascular territory. At a 98-micron strut thickness across all its usable range of diameters, the MAGNITUDE BRS device is the thinnest BRS ever tested in this clinical setting.
“Given the dire and unmet clinical need of patients presenting with CLI undergoing BTK revascularization, we are extremely pleased by the rapid progression of our program,” said R3 Vascular CEO Kamal Ramzipoor. “Our MAGNITUDE BRS is well-positioned to improve the clinical outcomes of these patients by providing temporary mechanical support and sustained drug delivery while reducing the well-established complications associated with permanent implants.”
“In this early clinical experience, we successfully tested the deliverability and mechanical performance of the MAGNITUDE BRS. Post-procedural angiographic and duplex ultrasound data confirms the mechanical properties and ‘stent-like’ results of the MAGNITUDE BRS device in presence of a high-disease burden. We are looking forward to expanding the patient population cohort and following the clinical results over time,” said Dr. Marianne Brodman, Professor and Head, Clinical Division of Medical University of Graz, Austria.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?